Not quite the news we’re all waiting for, but none the less an extra two years of patent life in the US should increase the value and attractiveness of PD1-Vaxx for any licensing deal negotiations.
Ann: Imugene PD1-Vaxx patent extended to 2040, page-2
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $563.6M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.7¢ | $303.3K | 3.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 668805 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.8¢ | 352547 | 12 |
View Market Depth
| Last trade - 10.37am 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 1.43 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 2605993 | ||
| Last updated 10.56am 07/05/2024 ? | |||||
| IMU (ASX) Chart |